ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 135 filers reported holding ASCENDIS PHARMA A/S in Q2 2019. The put-call ratio across all filers is 0.27 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $33,137,000 | +2018.7% | 251,900 | +1713.7% | 8.24% | +1472.1% |
| Q1 2020 | $1,564,000 | -85.3% | 13,889 | -84.6% | 0.52% | -81.7% |
| Q1 2019 | $10,631,000 | +370.2% | 90,325 | -19.7% | 2.87% | +84.1% |
| Q3 2016 | $2,261,000 | -15.9% | 112,497 | -44.5% | 1.56% | +13.5% |
| Q2 2016 | $2,687,000 | -22.6% | 202,520 | +8.2% | 1.37% | +8.0% |
| Q1 2016 | $3,473,000 | -33.4% | 187,220 | -34.3% | 1.27% | -45.0% |
| Q4 2015 | $5,217,000 | +9.3% | 284,785 | +5.6% | 2.31% | -29.4% |
| Q3 2015 | $4,775,000 | +33.3% | 269,785 | +33.2% | 3.27% | +85.0% |
| Q2 2015 | $3,581,000 | – | 202,525 | – | 1.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |